10-Q: Bioxytran Inc. Q1 2026 Financials: Net Loss Widens Amidst Funding Concerns

Bioxytran Inc. reported a net loss of $2.07 million for Q1 2026, an increase from the prior year, while facing substantial doubt about its ability to continue as a going concern due to insufficient capital.

Summary

• Bioxytran Inc. reported a net loss of $2,068,989 for the first quarter ended March 31, 2026, compared to a net loss of $1,353,635 for the same period in 2025.
• The company's cash balance decreased to $463,047 as of March 31, 2026, from $509,914 as of December 31, 2025.
• Total liabilities increased to $5,010,121 as of March 31, 2026, from $3,249,894 as of December 31, 2025.
• The company has an accumulated deficit of $23,113,235 as of March 31, 2026.
• Research and development expenses decreased to $225,479 in Q1 2026 from $349,500 in Q1 2025.
• General and administrative expenses significantly increased to $1,707,574 in Q1 2026 from $165,642 in Q1 2025, largely due to a substantial stock-based compensation award to the CEO.
• The company is actively seeking to raise approximately $2-3 million in 2026 to fund operations for the next 15 months, acknowledging that current cash is insufficient beyond September 2026.
• The company's Phase 3 trial for ProLectin-M is projected to start in Q3 2026, contingent on adequate funding.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the widening net loss, increased liabilities, and significant concerns about the company's ability to continue as a going concern, despite some positive clinical trial data.

Positives

• The Phase 1b/2a study for ProLectin-M showed statistically significant earlier viral clearance and faster clinical improvement by Day 5 in mild to moderate COVID-19 patients, with a favorable safety profile.
• The company secured $241,040 in net cash proceeds from a private placement of stock and warrants during Q1 2026.
• The company has a pipeline focused on therapeutic molecules for stroke (BXT-25) and COVID-19 treatments (ProLectin-M, ProLectin-I, ProLectin-F).
• The company's Acellular Oxygen Carrier (AOC) BXT-25 has shown encouraging initial results in animal testing, demonstrating non-toxicity and full recovery in mice.

Negatives

• The company reported a net loss of $2,068,989 for Q1 2026, an increase from $1,353,635 in Q1 2025.
• The company has substantial doubt about its ability to continue as a going concern due to insufficient capital resources.
• Cash on hand is not sufficient to fund projected operating requirements through September 2026.
• Total liabilities increased significantly to $5,010,121 as of March 31, 2026, from $3,249,894 as of December 31, 2025.
• The company's accumulated deficit stands at $23,113,235 as of March 31, 2026.
• General and administrative expenses saw a significant increase due to a large stock-based compensation award to the CEO.
• The 2021 Note is in default since March 1, 2025, with a default interest rate of 18%.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to insufficient capital resources.
• Failure to raise sufficient additional funds could lead to the need to extend payables, reduce overhead, or scale back the business plan.
• The company may be forced to curtail or cease operations if additional capital cannot be raised from conventional sources or through stock sales.
• The 2021 Note is in default, and its conversion could lead to substantial dilution to shareholders due to the conversion discount.
• The company faces risks related to regulatory approvals, market conditions, and the success of clinical trials for its drug candidates.
• A material weakness in internal controls over financial reporting exists due to a lack of segregation of duties and the need for a stronger internal control environment.

Future Outlook

The company believes it needs to raise approximately $3.7 million to fund operations for the next 15 months. Without sufficient funding, the company may have to scale back its business plan or cease operations. The Phase 3 trial for ProLectin-M is projected to start in the third quarter of 2026, contingent on adequate funding.

Management Comments

• Dr. Platt expressed, and named, the Human Galectin-3 protein coded by a single gene, LGALS3, located on chromosome 14. Galectin inhibitors block the binding of galectins to carbohydrate structures, present in numerous disease indications by reducing the inflammatory feedback loop associated with the chronic diseases. The galectin inhibitors also have the capability to neutralize the spike proteins of a number of viruses which reduces their capability to replicate.
• Management is aware that current cash on hand will not be sufficient to fund projected operating requirements through September 2026 and is pursuing alternative funding opportunities.
• Management believes that if they can raise $3,700,000, they will have sufficient working capital to develop their business over the next approximately fifteen (15) months.

Industry Context

StockSavvy.ai notes that Bioxytran operates in the highly competitive and capital-intensive clinical-stage pharmaceutical sector, where success is heavily dependent on successful clinical trials, regulatory approvals, and significant funding. The company's focus on novel carbohydrate drug design for viral diseases and degenerative conditions aligns with emerging trends in drug discovery, but the path to commercialization is fraught with risk and requires substantial investment.

Comparison to Industry Standards

• The company's net loss of $2.07 million for the quarter is substantial for a clinical-stage company, but not uncommon given the high R&D costs and lack of revenue. Many biotech companies in this stage experience significant losses.
• The company's cash burn rate, while concerning, is being managed through ongoing financing activities. However, the need for $2-3 million in additional capital highlights the typical funding challenges faced by early-stage biotechs.
• The reported progress on ProLectin-M's Phase 1b/2a study, showing positive viral clearance and clinical improvement, is a critical milestone. Similar early-stage trial results in the industry often pave the way for progression to Phase 3, but success is not guaranteed.
• The company's reliance on private placements for funding is standard practice for companies at this stage, though it carries dilution risks for existing shareholders, a common concern across the industry.

Corporate Governance

Legal Proceedings

• A former officer contested termination for cause and filed a worker rights complaint with the state of Washington. The company has contested the complaint. Reserves of $157,500 were recorded for disputed compensation and expense reimbursement claims by the former Chief Commercial Officer.
• On May 1, 2026, the State of Washington Department of Labor and Industries determined a former officer's worker rights complaint was justified, assessing $170,887.50 plus interest. The company contests this decision.

Related Party Transactions

• Accounts payable to affiliates increased to $869,237 as of March 31, 2026, from $647,959 as of December 31, 2025.
• Un-issued shares liability to affiliates was $1,360,606 as of March 31, 2026, compared to $82,006 as of December 31, 2025.
• Loan from affiliates was $355,598 as of March 31, 2026, down from $395,668 as of December 31, 2025.
• Interest expense to affiliates was $24,963 for the three months ended March 31, 2026.
• Stock-based compensation expense to affiliates was $1,278,600 for the three months ended March 31, 2026.
• The company holds a license agreement with an affiliated company where company officers hold a majority interest, with annual maintenance costs of $5,000.
• On January 30, 2026, the company granted 6,000,000 shares of Convertible Preferred Stock to Dr. Platt as a performance grant.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and the conversion of convertible notes.
• Employees may be impacted by potential scaling back of business plans or cessation of operations if funding is not secured.
• Creditors and suppliers may face extended payment terms or uncertainty if the company cannot meet its financial obligations.
• Management and Directors' compensation is significantly tied to stock-based awards, which increased substantially in the current quarter.

Next Steps

• Obtain adequate funding to support further development activities and sustain operations.
• Proceed with Phase 3 application for ProLectin-M.
• Projected start of Phase 3 trial for ProLectin-M in the third quarter of 2026, contingent on funding.
• Conduct a 14-day repeated dose toxicity study using New Zealand Rabbits and Wistar Rats for BXT-25, as funding permits.

Key Dates

Recommendation

The company shows promising clinical data for its lead drug candidate, ProLectin-M, which could be a significant catalyst. However, the severe financial distress, including the going concern warning and substantial increase in liabilities, presents a high-risk profile. Investors should hold positions while monitoring the company's ability to secure critical funding, as a failure to do so could render the clinical progress moot. The potential for dilution from future financing also warrants caution.

Keywords

Bioxytran, 10-Q, Quarterly Report, Pharmaceutical, Clinical Stage, Drug Development, COVID-19, Stroke Treatment, Net Loss, Going Concern, Capital Raise, Stock-based Compensation, Convertible Notes, Warrants